AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT03103399
Drug: Comtan®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg entacapone were to be taken concomitantly with each levodopa/DDCI dose.
Trial: NCT03103399
Drug: Levodopa/DDCI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prior to the study, all patients were to have been receiving levodopa/DDCI therapy for at least 1 year with clear clinical improvement. At entry to the study, patients were to be receiving levodopa/DDCI therapy of at least 4 but not more than 8 (inclusive) standard daily doses.~All patients were to continue receiving levodopa/DDCI during the study. Levodopa and DDCI were prescribed by the investigators and purchased locally by patients.
Trial: NCT03103399
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally as encapsulated tablets, which were identical in appearance to the study drugs
Trial: NCT03388970
Drug: Vitamin K 1
RxNorm normalized name: vitamin K 1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Research group use Vitamin K1
Trial: NCT03388970
Drug: normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo group use normal saline
Trial: NCT00252863
Drug: Symbicort, used twice daily (b.i.d) and as needed (prn)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00252863
Drug: Theophylline 200 mg
RxNorm normalized name: theophylline 200 MG
DrugBank: Theophylline (DB00277)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00252863
Drug: Theophylline 300 mg
RxNorm normalized name: theophylline 300 MG
DrugBank: Theophylline (DB00277)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01383941
Drug: Guidelines-based asthma and rhinitis/rhinosinusitis therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All participants receive standardized asthma and rhinitis treatment. Asthma and rhinitis medication regimens were based on 1.) the National Asthma Education and Prevention Program (NAEPP) Expert Panel Report -3 (EPR-3) and 2.) the Rhinitis and its Impact on Asthma (ARIA) 2008 guidelines-derived treatment algorithms. References: 1.) J Allergy Clin Immunol 2007; Volume 120, Issue 5, Supplement s93-140. 2.) Allergy 2008; Volume 63, Issue Supplement s86, pages 7-160.
Trial: NCT03952130
Drug: LY900014
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered SC
Trial: NCT03933501
Drug: Placebos
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two distinct placebo pills prescribed on the day of treatment and taken every 8 hours for 7 days.
Trial: NCT02396147
Drug: TAK-385 T2 Formulation
RxNorm normalized name: Hep B, unspecified formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TAK-385 T2 Formulation tablets
Trial: NCT02396147
Drug: TAK-385 T4 Formulation B
RxNorm normalized name: Hep B, unspecified formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TAK-385 T4 Formulation B tablets
Trial: NCT02832271
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT04889677
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01583647
Drug: MK-0524A
RxNorm normalized name: vitamin MK 7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 tablet of MK-0524A (1g ER niacin/20mg laropripant) orally
Trial: NCT01583647
Drug: MK-0524A
RxNorm normalized name: vitamin MK 7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 tablets of MK-0524A (1g ER niacin/20mg laropripant) orally
Trial: NCT02325882
Drug: Fentanyl 1
RxNorm normalized name: fentanyl 1.2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: conventional fentanyl-based epidural PCA
Trial: NCT02325882
Drug: Fentanyl 2
RxNorm normalized name: fentanyl 2.5 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: conventional fentanyl based intravenous PCA
Trial: NCT02652819
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01718314
Drug: Placebo (for Misoprostol)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lactose filler, the pharmacy-produced pills identical to original misoprostol pill
Trial: NCT01718314
Drug: Placebo (for Lidocaine)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The pharmacy-produced sterile saline containing pump spray external characteristics identical to lidocaine pump spray
Trial: NCT00719810
Drug: tigecycline
RxNorm normalized name: Tigecycline
DrugBank: Tigecycline (DB00560)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 100 mg then 50 mg intravenous tigecycline every 12 hours
Trial: NCT03067597
Drug: Dinoprostone
RxNorm normalized name: Dinoprostone
DrugBank: Dinoprostone (DB00917)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: The DVI contains 10 mg dinoprostone
Trial: NCT03976401
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered by subcutaneous injection
Trial: NCT03088605
Drug: TOP1630 Ophthalmic Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bilateral ocular drug administration
Trial: NCT03088605
Drug: Placebo to TOP1630 Ophthalmic Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bilateral ocular drug administration
Trial: NCT00262106
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT00149214
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 600 mg/m2, intravenous (IV), every 21 days, 4 cycles (1-4)
Trial: NCT00149214
Drug: doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 60 mg/m\^2, intravenous (IV), every 21 days, 4 cycles (1-4)
Trial: NCT02282761
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01382069
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo with capsules that look like the DMAU capsules but with no active ingredients
Trial: NCT00184990
Drug: endotoxin
RxNorm normalized name: Endotoxin
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01673061
Drug: Vapocoolant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: See associated Arm Description
Trial: NCT02439385
Drug: Avastin/FOLFIRI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Avastin: 5mg/kg iv on day1, every 14 days. Irinotecan: 180 mg /m2 iv on day1, every 14 days. Leucovorin: 200 mg/m2 iv on day1,2 every 14 days. 5-fluorouracil bolus: 400 mg/m2 iv on day1,2 every 14 days. 5-fluorouracil infusion: 1200 mg/m2 iv on day1,2 every 14 days.
Trial: NCT01690949
Drug: PUR118
FDA approved: no
EMA approved: no
PMDA approved: no
Description: inhaled PUR118, BID
Trial: NCT02201823
Drug: ABTL0812
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ABTL0812. Five cohorts and one extension phase.
Trial: NCT03749642
Drug: Placebo oral capsule
RxNorm normalized name: Placebo Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two capsules, three times a day, for 8 weeks.
Trial: NCT00005860
Drug: leucovorin calcium
RxNorm normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00923091
Drug: Olmesartan medoxomil + amlodipine + hydrochlorothiazide + placebo
RxNorm normalized name: amlodipine / hydrochlorothiazide / olmesartan medoxomil Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One olmesartan medoxomil 40 mg + amlodipine 5 mg combination oral tablet taken once per day. One hydrochlorothiazide 12.5 mg tablet + one hydrochlorothiazide 12.5 mg placebo tablet taken once per day.
Trial: NCT02140320
Drug: RV1729 single dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Safety and tolerability of single dose
Trial: NCT02140320
Drug: RV1729 matching placebo single dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Safety and tolerability of single dose
Trial: NCT02140320
Drug: RV1729 matching placebo 14 day repeat dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Safety and tolerability of repeat doses
Trial: NCT02140320
Drug: RV1729 matching placebo 28 day repeat dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Safety and tolerability of repeat doses
Trial: NCT00644319
Drug: ibuprofen
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01670500
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: administered with doxorubicin intravenously every 2 or 3 weeks for 4 doses
Trial: NCT01670500
Drug: Doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: administered with Cyclophosphamide intravenously every 2 or 3 weeks for 4 doses
Trial: NCT00491530
Drug: ABT-335
RxNorm normalized name: ABT-925
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral coadministration of ABT-335 (135 mg) once daily, beginning in either the 12-week double-blind study or the previous 52-week open-label year 1 study and continuing in 52-week year 2 study
Trial: NCT00491530
Drug: rosuvastatin calcium
RxNorm normalized name: Rosuvastatin Calcium
DrugBank: Rosuvastatin (DB01098)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oral coadministration of rosuvastatin calcium (20 mg) once daily, beginning in either the 12-week double-blind study or the previous 52-week open-label year 1 study and continuing in 52-week year 2 study
Trial: NCT00491530
Drug: simvastatin
RxNorm normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral coadministration of simvastatin (40 mg) once daily, beginning in either the 12-week double-blind study or the previous 52-week open-label year 1 study and continuing in 52-week year 2 study
Trial: NCT03598777
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The reconstituted solution will be injected intramuscularly across pelvic floor muscles.
Trial: NCT01703312
Drug: QGE031
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug administered by subcutaneous injection
Trial: NCT01703312
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug administered by subcutaneous injection
Trial: NCT00649961
Drug: Melatonin injection
DrugBank: Melatonin (DB01065)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: A single intravenous infusion of melatonin will be given to each infant over 6 hours so that successive groups will receive increasing doses until the correct dose for age is found.~Based on the pharmacokinetics and clearance of melatonin in adults an approximate dose has been calculated. The starting dose of melatonin will be 0.1 microgram/kg/hr to be given over 6 hours intravenously. The range of expected dose is 0.1-0.5 microgram/kg/hr.
Trial: NCT02519231
Drug: Naproxen
RxNorm normalized name: Naproxen
DrugBank: Naproxen (DB00788)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Naproxen 440mg 1x pid
Trial: NCT02519231
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablet 440mg 1x pid
Trial: NCT01859351
Drug: WX-037
RxNorm normalized name: WX-554
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01859351
Drug: WX-554
RxNorm normalized name: WX-554
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03740217
Drug: GKT137831
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral bioavailable small molecule that selectively inhibit NOX1 and NOX4
Trial: NCT03667131
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo 5 mg tablet, every 12 hrs for 90 days.
Trial: NCT01421368
Drug: Oral contraceptive: LNG 150 mcg and EE 30 mcg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Each pill contains LNG 150 mcg (the active levorotatory enantiomer of norgestrel) and EE 30 mcg. Each pack contains 21 active pills and 7 placebo pills
Trial: NCT00315601
Drug: Telithromycin
RxNorm normalized name: Telithromycin
DrugBank: Telithromycin (DB00976)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 800 mg once a day for 5 days
Trial: NCT00315601
Drug: azithromycin
RxNorm normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 500 mg on day 1, and then 250 mg once-daily on days 2 through 5
Trial: NCT00315601
Drug: Telithromycin
RxNorm normalized name: Telithromycin
DrugBank: Telithromycin (DB00976)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Telithromycin 800 mg once a day
Trial: NCT02862912
Drug: Fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 15 mcg Fentanyl will be included int he spinal anesthetic in both groups
Trial: NCT00035815
Drug: Insulin like growth factor, type 1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.05 mg per kg body weight given subcutaneously twice daily
Trial: NCT00035815
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The placebo represented the inert suspension vehicle for the IGF-1. It was given as equal volume as the active drug based upon body weight, subcutaneously twice daily.
Trial: NCT03166800
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: This arm of the intervention the study subject will be administered placebo capsules to orally take every morning for 12 weeks.
Trial: NCT03401606
Drug: remifentanil
RxNorm normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: remifentanil, 0.25 ng/mL, given intravenous, infusion, until surgery finished
Trial: NCT00621023
Drug: Decitabine, Arsenic Trioxide and Ascorbic Acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects receive decitabine 20 mg/m2 IV over one hour for days1-5 of each cycle, and arsenic trioxide 0.25 mg/kg IV for days 1-5 of cycle 1 followed by 0.25 mg/kg twice weekly (Mon-Thursday or Tues-Fri) for all remaining cycles. Patients will have transfusion and supportive care therapy administered per the treating physician's discretion. Patients with a response after 4 cycles of therapy may choose to continue on two more cycles of decitabine with arsenic and ascorbic acid given only during the first week of those two additional cycles.
Trial: NCT00749099
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 capsules of a placebo drug (Phase I) with a standardized Lundh meal.~Gastric samples are collect once an hour and duodenal samples are collected every 15 minutes for each phase (4 hours each).
Trial: NCT02513940
Drug: Testosterone
RxNorm normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Subjects will receive transdermal testosterone gel 1% 100 mg daily for 7 days
Trial: NCT02513940
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will receive placebo transdermal gel and placebo (lactose) capsules
Trial: NCT01855230
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo b.i.d. for 14 days
Trial: NCT03321617
Drug: Pomaglumetad methionil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: metabotropic glutamate 2/3 receptor (mGlu2/3R) agonist
Trial: NCT01794897
Drug: Placebo comparator
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will have a placebo run-in for two weeks after which they will be evaluated for the variables of interest and then randomized to either VAV or placebo group in a 1:1 proportion. Subjects in the placebo arm will receive placebo for 16 weeks, after which they will be followed up without placebo for 4 weeks to monitor delayed adverse effects.
Trial: NCT00465140
Drug: creatine supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04277702
Drug: Standard anti-platelet treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard antithrombotic treatment for patients undergoing endovascular procedures
Trial: NCT00936897
Drug: Ibandronate
RxNorm normalized name: ibandronate
DrugBank: Ibandronate (DB00710)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibandronate 150mg PO QM (tablet)
Trial: NCT03899870
Drug: Neoadjuvant therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients with locally advanced disease (T3, T4) or lymph nodal positive disease were offered neoadjuvant therapy. In the neoadjuvant therapy, we used 45 Gy in 25 fractions with concurrent 5-fluorouracil \[5-FU\] and patients were operated 8 to 10 weeks after neoadjuvant therapy. In some cases, especially the elderly patients with multiple co-morbidities, we used short-course pelvic radiation therapy which included 25 Gy in 5 fractions over 1 week.
Trial: NCT04482673
Drug: Daily placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo daily
Trial: NCT04482673
Drug: Bolus placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bolus placebo daily for 3 days
Trial: NCT03090672
Drug: Normal Saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal Saline IV delivery
Trial: NCT01133119
Drug: Standard of Care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will have femoral sheaths removed under general anesthetic but without subcutaneous infiltration of bupivacaine.
Trial: NCT01804205
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 ml of 0.9% physiological saline, for 10 min, and then continuous intravenous infusion of saline at a rate of 33 ml/h during the surgical procedure until the maximum of 3 h
Trial: NCT02260011
Drug: Atrovent® CFC inhalation aerosol
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04265534
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral placebo
Trial: NCT03899870
Drug: Adjuvant therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients with locally advanced disease (T3, T4) or lymph nodal positive disease were offered adjuvant therapy. In most of the cases, FOLFOX (leucovorin, 5-FU, oxaliplatin) regimen was used and for elderly patients who could not tolerated this regimen, we used oral capecitabine.
Trial: NCT01615445
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive placebo daily for 4 weeks, followed by no medication for two weeks and then resveratrol 1 000 mg(500 mg twice) daily for 1 week, then by tolerance and safety 2 000 mg (1 000 mg twice) daily for three weeks.
Trial: NCT02006030
Drug: Transarterial chemoembolization
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04173533
Drug: Matched placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral azacitidine (CC-486) matched placebo tablet
Trial: NCT04382794
Drug: Retrospective case-control analysis
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Evaluation of clinical, laboratory and instrumental parameters of diabetic patients during hospitalization for COVID-19. The data will be extracted anonymously from the computerized medical records commonly used in clinical practice by the centers involved in the study
Trial: NCT02908438
Drug: Gonadotrophin releasing hormone agonist(GnRHa)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GnRHa group receive three injections of GnRHa(Decapeptyl) ,0.1 mg s.c. on the day of ET, and D3 and D6 after ET in addition to routine LPS.
Trial: NCT04538014
Drug: [11C]-Lu AF88434
FDA approved: no
EMA approved: no
PMDA approved: no
Description: \[11C\]-Lu AF88434, and a radioactive dose not exceeding 400 MBq at each PET examination, intravenous bolus injection
Trial: NCT02984501
Drug: Chemotherapy
RxNorm normalized name: Chemotherapy Glove SML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The induction phase of the treatment plan is designed to administer gemcitabine 1000 mg/mq and oxaliplatin 100 mg/mq every 14 days for four doses. Chemotherapy concurrent to conformal radiation therapy is gemcitabine at the dose of 600 mg/mq weekly.
Trial: NCT01466114
Drug: estriol
RxNorm normalized name: Estriol
DrugBank: Estriol (DB04573)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 capsules of 2 mg (total of 8 mg) PO QD
Trial: NCT04252417
Drug: MD1003
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single oral dose administration of MD1003 at Day 1
Trial: NCT00000249
Drug: 20% N2O
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20% inhaled N2O
Trial: NCT00000249
Drug: 30% N2O
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30% inhaled N2O
Trial: NCT03900676
Drug: VB-1953 - 2%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical Gel
Trial: NCT01380093
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-dose, 2 x microcrystalline cellulose (weighed to equal weights of average tablet/capsule of active comparator) mixed with 150 ml artificially sweetened, non-carbonated beverage
Trial: NCT00765115
Drug: LY450139
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00765115
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01822860
Drug: Chlorthalidone 12.5 mg
RxNorm normalized name: chlorthalidone 12.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01822860
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03952650
Drug: ibuprofen
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Ibuprofen likewise is not a part of the investigational product/regimen, but will be provided to participants in the chloroquine arm (Arm 4) if required to mitigate typical symptoms of malaria infection such as headache, myalgia, fever and chills.
Trial: NCT01573468
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo orally once on Day 1 of each cycle
Trial: NCT01573468
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Capecitabine 1750 mg/m2/day orally twice daily (in 2 equally divided doses) on Days 1-14 of each cycle